The widespread adoption of GLP-1 medications like semaglutide and tirzepatide has raised critical questions about what happens when patients stop taking these expensive treatments. New evidence from nearly 8,000 patients suggests the outcome may be more favorable than expected, challenging assumptions about inevitable weight rebound.
Patients who used these medications for obesity lost an average of 8.4% of their body weight before discontinuing, while those treated for diabetes lost 4.4%. Most remarkably, one year after stopping the drugs, obesity patients maintained their weight loss almost entirely, gaining back only 0.5% on average. Diabetes patients actually continued losing weight, dropping an additional 1.3% post-discontinuation. Within the year following discontinuation, more than half of patients pursued additional interventions: 19.6% restarted their original medication, 27.4% switched to alternative weight-loss drugs, and 13.7% engaged in structured lifestyle modification programs.
This real-world data contradicts the prevailing narrative that stopping GLP-1 medications inevitably leads to rapid weight regain. The sustained benefits likely reflect both the metabolic reset these drugs provide and patients' continued engagement with weight management strategies. However, the study's observational design cannot establish whether the maintained weight loss stems from the drugs' lasting effects, behavioral changes, or selection bias toward more motivated patients. The considerable individual variation in outcomes suggests personalized discontinuation strategies may be crucial. For the growing population using these medications, this research indicates that temporary use might still provide lasting benefits, potentially reshaping treatment approaches and insurance coverage decisions.